http://www.reprosrx.com http://tinyurl.com/yeoe2d http://www.reprosrx.com/investors_events.php http://finance.yahoo.com/q/ks?s=RPRX+Key+Statistics
Repros Therapeutics Inc., a development stage biopharmaceutical company, focused on the development of new drugs to treat hormonal and reproductive system disorders. It is developing Androxal, an oral therapy that normalizes testicular function for the treatment of low testosterone due to secondary hypogonadism. The company is also conducting a phase 2 study of the use of Androxal in the treatment of type 2 diabetes in hypogonadal men. In addition, it is developing Proellex, an orally administered selective blocker of the progesterone receptor in women for the treatment of uterine fibroids and endometriosis; and phentolamine-based product candidate VASOMAX for the treatment of male erectile dysfunction. The company was formerly known as Zonagen, Inc. and changed its name to Repros Therapeutics, Inc. in May 2006. Repros Therapeutics, Inc. was founded in 1987 and is based in The Woodlands, Texas.